| Patient | Ella Fitzgerald |
|---|---|
| Date of birth | 1917-04-25 |
| Identifiers | MRN HR-ML029-SYN-TD; SSN (made up) 000-29-3640 |
| Document date | 1987-10-26 |
| Author | Odessa Whitlow, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Five-and-a-half-month review: A1c, lipids, walking distance, the revascularization decision, foot and eye follow-up. [S]
Ms. Fitzgerald returns eleven weeks after her three-month visit. She stepped up to semaglutide 0.5 mg weekly in September; she had mild nausea for the first two weeks, which passed, and she has lost 1.5 kg. Her glucose monitor shows time in range 74% and time below 70 mg/dL 0.6%, with no reading below 54 mg/dL. She finished the supervised exercise program and walks most days; she can now walk about five blocks before calf pain, and only climbing slows her. She has no rest pain and no sores. She has had five right-eye injections and the interval is now eight weeks. The podiatrist saw her in September. She has had no bleeding. Her mammogram in July was normal, and the bone density scan is booked between tours. She feels ready for her winter tour. [S]
| Element | Detail |
|---|---|
| Glucose | Time in range 74%; time below 70 mg/dL 0.6%; none below 54 |
| Semaglutide | 0.5 mg weekly since September; nausea passed |
| Walking | About five blocks; no rest pain |
| Eye treatment | Five injections; now every eight weeks |
| System | Result | Finding |
|---|---|---|
| Cardiovascular | Positive | Calf pain only after about five blocks or on hills; no chest pain |
| Gastrointestinal | Negative | Nausea resolved; no vomiting or abdominal pain |
| Eyes | Negative | Right-eye vision clearer |
| Integumentary | Negative | No foot sores |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin 1000 mg oral tablet, one tablet by mouth twice daily with meals | One tablet by mouth twice daily with breakfast and the evening meal | Oral route | 1977-03-01 | active | S |
| Glipizide 10 mg oral tablet, one tablet by mouth twice daily before meals | One tablet by mouth twice daily before breakfast and the evening meal | Oral route | 1982-09-01 to 1987-05-11 | completed | S |
| Insulin glargine 100 units/mL pen, 30 units under the skin at bedtime | 30 units at bedtime | Subcutaneous route | 1984-04-01 to 1987-05-11 | completed | S |
| Insulin glargine 100 units/mL pen, 24 units under the skin each morning | 24 units each morning, at the same clock time on tour, with written time-zone adjustments | Subcutaneous route | 1987-05-11 | active | S |
| Atorvastatin 40 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1986-06-02 to 1987-05-11 | completed | S |
| Atorvastatin 80 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1987-05-11 | active | S |
| Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1986-06-02 | active | S |
| Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1986-06-02 | active | S |
| Empagliflozin 10 mg oral tablet, one tablet by mouth each morning | One tablet by mouth each morning; hold on days she cannot eat or drink normally and before surgery | Oral route | 1987-05-11 | active | S |
| Glucagon 3 mg nasal powder, one spray into one nostril for a severe low glucose | One spray into one nostril if she cannot safely swallow during a low glucose; may repeat once after 15 minutes with a new device; call 911 | Nasal route | 1987-05-11 | active | S |
| Rivaroxaban 2.5 mg oral tablet, one tablet by mouth twice daily with aspirin 81 mg | One tablet by mouth twice daily, with aspirin 81 mg once daily | Oral route | 1987-05-26 | active | S |
| Semaglutide 0.25 mg under the skin once weekly for four weeks | 0.25 mg once weekly on the same day each week for four weeks | Subcutaneous route | 1987-08-10 to 1987-09-07 | completed | S |
| Semaglutide 0.5 mg under the skin once weekly | 0.5 mg once weekly on the same day each week | Subcutaneous route | 1987-09-07 | active | S |
| Ezetimibe 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1987-08-10 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1987-10-26 | Body height | 165 | cm | S |
| 1987-10-26 | Body weight | 80.6 | kg | S |
| 1987-10-26 | Body mass index (BMI) [Ratio] | 29.6 | kg/m2 | S |
| 1987-10-26 | Systolic blood pressure | 120 | mm[Hg] | S |
| 1987-10-26 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 1987-10-26 | Heart rate | 60 | /min | S |
| 1987-10-26 | Respiratory rate | 16 | /min | S |
| 1987-10-26 | Body temperature | 36.6 | Cel | S |
| 1987-10-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1987-10-26 | Hemoglobin A1c/Hemoglobin.total in Blood | 7.1 | % | Below 5.7% is normal; her individualized goal is below 7.5% | High | S |
| 1987-10-26 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 1987-10-26 | Potassium [Moles/volume] in Serum or Plasma | 4.5 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1987-10-26 | Creatinine [Mass/volume] in Serum or Plasma | 0.94 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1987-10-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1982)/1.73 sq M | 65 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1987-10-26 | Cholesterol [Mass/volume] in Serum or Plasma | 114 | mg/dL | <=199 mg/dL | Normal | S |
| 1987-10-26 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 48 | mg/dL | Her goal with coronary and peripheral artery disease is below 55 mg/dL | Normal | S |
| 1987-10-26 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 47 | mg/dL | >=50 mg/dL | Low | S |
| 1987-10-26 | Triglyceride [Mass/volume] in Serum or Plasma | 96 | mg/dL | <=149 mg/dL | Normal | S |
| 1987-10-26 | Visual acuity best corrected Right eye by ETDRS eye chart | 75 | {letters} | 85 letters is about 20/20; 80 about 20/25; 65 about 20/50 | Low | S |
| 1987-10-26 | Visual acuity best corrected Left eye by ETDRS eye chart | 81 | {letters} | 85 letters is about 20/20; 80 about 20/25; 65 about 20/50 | Normal | S |
Vital signs recorded on 1987-10-26; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 80.6 kg, BMI 29.6; blood pressure 120/68, pulse 60 |
| Feet | Skin intact; minimal callus; hammer toes; no ulcer; monofilament felt at all sites; right foot pulses absent, left faint; feet warm |
| Eyes | Best-corrected acuity 75 letters right and 81 letters left |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Type 2 diabetes mellitus with peripheral artery disease: cramping in both calves after about one and a half blocks of walking, worse on the right, easing within minutes of rest; no rest pain, wounds, or color change. Resting ankle-brachial index 0.62 right and 0.74 left, toe-brachial index 0.46 and 0.55; dorsalis pedis and posterior tibial pulses absent on the right and faint on the left. A1c 8.6% on metformin, glipizide and glargine, with low glucose readings (to 52 mg/dL) after late performances. Foot: protective sensation intact to the 10-g monofilament at all sites and to vibration; callus under the second metatarsal heads; hammer toes of the second and third toes; no ulcer (IWGDF risk category 2). Synthetic modern episode linked to her documented diabetes and its circulatory complications | active | confirmed | E11.51 | S — Synthetic modern diagnosis; the type of diabetes was not made public and is synthetic. |
| Moderate nonproliferative diabetic retinopathy with center-involving diabetic macular edema in the right eye (best-corrected acuity 64 letters, about 20/50) and moderate nonproliferative retinopathy without macular edema in the left eye (81 letters); lens implants in both eyes from earlier cataract surgery. Synthetic modern episode linked to her documented diabetic eye problems | active | confirmed | E11.3311 | S — Synthetic modern eye diagnosis on retinal imaging and optical coherence tomography in the clinic; the left eye is described in the display. |
| Coronary artery disease after five-vessel coronary bypass surgery last year, with an intensive care stay; no angina now; on aspirin, a statin, and metoprolol. Synthetic modern episode linked to her documented heart surgery | active | confirmed | I25.10 | S — Synthetic modern coding of her documented heart surgery; bypass grafts are described in the display. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Hemoglobin A1c | Every three months when not at goal or after a change; every six months at goal | Completed today | 7.1%, at goal; every six months from now |
| Medication safety | Continuous glucose monitor review: time in range and time below range | Every visit | Completed today | Time in range 74%; time below 70 mg/dL 0.6% |
| Medication safety | Hypoglycemia events, show-day plan, and glucagon | Every visit | Completed today | No level 2 or 3 lows since intake |
| Medication safety | Empagliflozin safety: genital infection, volume, and sick-day rules | At the start and every visit | Completed today | No side effects |
| Laboratory | Creatinine, eGFR, and potassium | Within three months of starting an SGLT2 inhibitor, then every six to twelve months; potassium on SGLT2 inhibitor and rivaroxaban review | Completed today | Creatinine 0.94 mg/dL, eGFR 65, potassium 4.5, sodium 139 mmol/L |
| Laboratory | Urine albumin-creatinine ratio | Yearly | Up to date | 18 mg/g at intake; repeat at the next yearly check |
| Laboratory | Lipid panel | 4 to 12 weeks after a statin or other lipid-lowering change, then yearly | Completed today | LDL 48 mg/dL eleven weeks after ezetimibe was added, at goal |
| Examination | Foot inspection, protective sensation, and pulses | Every visit with peripheral artery disease and foot deformity (IWGDF risk 2); podiatry every three to six months | Completed today | No ulcer; podiatry in September; next in December |
| Imaging | Ankle-brachial and toe-brachial indices | At diagnosis; repeat with arterial duplex six months after the consultation or with any change in symptoms | Due | With arterial duplex at the vascular review next month, six months after the consultation |
| Examination | Walking distance and claudication symptoms | Every visit | Completed today | About five blocks; claudication no longer limits her |
| Self-management | Supervised exercise therapy | Three times a week for twelve weeks | Completed today | Program completed; walking most days |
| Imaging | Retinal examination and visual acuity | With each retina-clinic treatment while macular edema is treated; at least yearly in both eyes | Completed today | Acuity 75 letters right and 81 left; five injections |
| Examination | Blood pressure | Every visit | Completed today | 120/68 mmHg |
| Examination | Weight and BMI | Every visit | Completed today | 80.6 kg, down 3.4 kg since intake |
| Medication safety | Bleeding on rivaroxaban and aspirin | At the start and every visit | Completed today | No bleeding |
| Medication safety | Semaglutide tolerance: nausea, appetite, and dose step | At the start and each dose step | Completed today | 0.5 mg weekly; nausea passed |
| Self-management | Access and equity: tour-date scheduling, video visits, large print, drug costs | Every visit | Completed today | Video visit planned during the winter tour; prescriptions synchronized for travel |
Goal progress:
Immunizations given today: Influenza vaccine, high-dose, 1987-1988 season; Recombinant zoster vaccine, dose 1 of 2 [S]
Guideline basis: Standards of Care in Diabetes—2026 (2026); Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update) (2023); 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease (2024); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026); Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial (2025)
Follow-up: Vascular review with ankle-brachial index and duplex next month. Podiatry in December. Retina clinic every eight weeks. Video visit during the winter tour; in-person review in three months with A1c. [S]